valvular heart disease
Conditions
Interventions
E group:During anesthesia induction, 0.2% etomidate was given 0.3mg/kg
EP1 group:During induction of anesthesia, a mixture of 0.15-0.2ml/kg (0.2% etomidate 14mg + 1% propofol 30mg) was given
EP2 group:During induction of anesthesia, a mixture of 0.15-0.2ml/kg (0.2% etomidate 16mg + 1% propofol 20mg) was given
EP3 group:During anesthesia induction, a mixture of 0.15-0.2ml/kg (0.2% etomidate 18mg + 1% propofol 10mg) was given
Sponsors
Affiliated Hospital of Southwest Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Patients who need general anesthesia for cardiac membrane replacement under cardiopulmonary bypass; 2.Aged 18-70 years; 3.ASA classification II-III.
Exclusion criteria
Exclusion criteria: 1.Preoperative imaging showed by coronary stenosis; 2.Accompanied by severe hepatic and renal dysfunction; 3.Patients who are allergic with propofol or etomidate; 4.Left ventricular ejection fraction < 45%; 5.Abnormal funtion of adrenal cortex before operation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean arterial pressure;Heart rate;Stroke volume;Cardiac output;Cardiac index;Peripheral vascular resistance; | — |
Secondary
| Measure | Time frame |
|---|---|
| Injection pain;Myoclonia;Nausea and vomiting; | — |
Countries
China
Contacts
Public ContactLui Yulin
Affiliated Hospital of Southwest Medical University
Outcome results
None listed